#United States #AbbVie #North Chicago #Entenamig #CERVINO

AbbVie's Groundbreaking Phase 3 CERVINO Trial for Multiple Myeloma

A recent Phase 3 trial conducted by AbbVie, known as the CERVINO trial, has unveiled promising results for Entenamig, a novel therapeutic agent targeting relapsed or refractory multiple myeloma (RRMM) patients. The trial, which compared the efficacy of Entenamig against standard available therapies (SAT), demonstrated a statistically significant improvement in objective response rate (ORR) and progression-free survival (PFS).

Key Outcomes of the CERVINO Trial

Entenamig achieved an ORR of 74% when assessed against traditional treatments, which significantly surpassed the 45.7% ORR of the SAT group. Furthermore, the PFS was notably improved, with a hazard ratio of 0.40 indicating a 60% reduction in the risk of disease progression or death. These results highlight the potential of Entenamig as a frontline therapy for patients who have exhausted multiple prior treatment options, primarily those exposed to three different drug classes, including proteasome inhibitors, immunomodulators, and anti-CD38 monoclonal antibodies.

At the median follow-up of 11.4 months, the trial enrolled 393 participants, and the results indicated not only clinical significance but also a manageable safety profile. Importantly, fewer patients in the Entenamig group experienced severe treatment-related adverse events, suggesting its favorable tolerance in a patient population typically challenged by the side effects of existing therapies. Notably, the rate of cytokine release syndrome (CRS) was 28.3%, occurring predominantly at lower grades, and no grade 3 or higher events were reported.

Expert Insights

Dr. Peter Voorhees, the lead investigator and Chief of Plasma Cell Disorders Division at Atrium Health Levine Cancer Institute, emphasized the importance of these findings in enhancing treatment avenues for patients facing recurrent disease after several lines of therapy. He noted the manageable safety profile of Entenamig and its implications for patients across various healthcare settings, highlighting its potential for outpatient usage and broader access.

Addressing Unmet Medical Needs

The advent of dual-targeting therapies such as Entenamig is critical, particularly in light of the limitations posed by the current treatment landscape for multiple myeloma. While existing therapies have greatly altered clinical practices, they are often accompanied by challenges including CRS, neurotoxicity, and severe infections. The availability of new therapeutic options like Entenamig is crucial for addressing the ongoing unmet needs among the RRMM patient population, especially in community care settings where access to specialized healthcare may be limited.

AbbVie’s Commitment to Oncology

Daejin Abidoye, M.D., AbbVie's Vice President and Head of the Oncology Therapeutic Area, remarked on the supportive data emerging from the CERVINO trial, reinforcing the company’s commitment to advancing treatment paradigms in multiple myeloma. The design of Entenamig not only strives to enhance clinical outcomes but also aims to accommodate the practical needs of patients and healthcare practitioners alike. AbbVie continues to explore complementary T-cell engaging therapies and targeted small molecules to provide a robust strategy against multiple myeloma’s evolving challenges.

Next Steps and Future Directions

The findings of the CERVINO trial will be formally presented during the plenary session at the 23rd International Myeloma Society Annual Meeting, set to take place in Glasgow, Scotland, from September 23 to 26, 2026. As patient treatment options expand, ongoing clinical trials will be pivotal in validating Entenamig’s efficacy further and determining its role in the broader spectrum of multiple myeloma therapy.

AbbVie’s mission is to provide innovative solutions that address significant health challenges, and the results of the CERVINO trial represent a significant stride forward in creating effective treatment strategies for those battling multiple myeloma.

For ongoing updates and future developments regarding Entenamig and AbbVie’s oncology pipeline, stakeholders are encouraged to refer to clinicaltrials.gov and AbbVie’s oncology webpage.